XML 19 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Cash flows from operating activities              
Net loss $ (1,976,012) $ (2,027,579) $ (203,460) $ (2,009,596) $ (5,797,365) $ (4,258,279)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock-based compensation expense 172,352   247,390   737,844 851,471  
Amortization of held-to-maturity securities, net         (20,750) (52,037)  
Amortization of debt issuance costs         36,104 43,961  
Gain from the sale of investment in Alphazyme         (60,977)  
Foreign currency exchange loss (gain), net         35,924 14,044  
Changes in operating assets and liabilities:              
Interest receivable         (9,869) (30,752)  
Accounts receivable         (673,302) 114,814  
Prepaid expenses and other current assets         (36,916) (46,386)  
Operating lease assets and liabilities         (133) 1,163  
Accounts payable         681,546 (109,426)  
Accrued expenses         633,522 121,623  
Accrued interest         (20,000) 80,000  
Accrued interest - related party         (2,040) 28,000  
Deferred research and development obligations         503,325 24,370  
Net cash (used in) operating activities         (3,932,110) (3,278,411)  
Cash flows from investing activities              
Purchases of held-to-maturity investment securities         (5,090,846) (5,971,505)  
Proceeds from maturities of investment securities         4,704,772 2,771,000  
Proceeds from the sale of investment in Alphazyme         60,977  
Net cash (used in) investing activities         (386,074) (3,139,528)  
Cash flows from financing activities              
Proceeds from public offering, net of offering costs of $808,760         4,940,696  
Proceeds from exercise of stock         24,249  
Proceeds from issuance of convertible notes, net of issuance costs         3,882,884  
Proceeds from issuance of convertible notes, net of issuance costs - related party         1,941,442  
Net cash provided by financing activities         4,964,945 5,824,326  
Effect of exchange rate changes on cash         2,277 199  
Net decrease in cash, cash equivalents and restricted cash and cash equivalents         649,038 (593,414)  
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period   $ 6,506,750   $ 6,515,028 6,506,750 6,515,028 $ 6,515,028
Cash, cash equivalents and restricted cash and cash equivalents at end of period 7,155,788   5,921,614   7,155,788 5,921,614 6,506,750
Reconciliation of cash, cash equivalents, and restricted cash and cash equivalents to the consolidated balance sheets              
Cash and cash equivalents 5,834,510   5,921,614   5,834,510 5,921,614 6,506,750
Restricted cash and cash equivalents, current 1,321,278     1,321,278
Total cash, cash equivalents, and restricted cash and cash equivalents $ 7,155,788   $ 5,921,614   7,155,788 5,921,614  
Supplemental cash flow information              
Vesting of restricted stock units         269,100 664,086  
Conversion of convertible notes         600,000  
Cash paid for interest         425,907 149,778  
Supplemental noncash investing and financing information              
Fair value of warrants issued in connection with the offering         168,881  
Purchase and assignment of convertible note by related party         $ 1,000,000